Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.
2.

HIV protease inhibitors and insulin resistance: lessons from in-vitro, rodent and healthy human volunteer models.

Hruz PW.

Curr Opin HIV AIDS. 2008 Nov;3(6):660-5. doi: 10.1097/COH.0b013e3283139134.

3.

Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus.

Grinspoon SK.

Am J Med. 2005 Apr;118 Suppl 2:23S-28S. Review.

PMID:
15903292
4.
5.

Altered myocellular and abdominal fat partitioning predict disturbance in insulin action in HIV protease inhibitor-related lipodystrophy.

Gan SK, Samaras K, Thompson CH, Kraegen EW, Carr A, Cooper DA, Chisholm DJ.

Diabetes. 2002 Nov;51(11):3163-9.

6.
7.

Serum adipocytokines are related to lipodystrophy and metabolic disorders in HIV-infected men under antiretroviral therapy.

Vigouroux C, Maachi M, Nguyên TH, Coussieu C, Gharakhanian S, Funahashi T, Matsuzawa Y, Shimomura I, Rozenbaum W, Capeau J, Bastard JP.

AIDS. 2003 Jul 4;17(10):1503-11.

PMID:
12824788
8.

Insulin resistance in HIV-related lipodystrophy.

Mikhail N.

Curr Hypertens Rep. 2003 Apr;5(2):117-21. Review.

PMID:
12642010
9.

[HIV infection, antiretroviral therapy, and endothelium].

Hürlimann D, Weber R, Enseleit F, Lüscher TF.

Herz. 2005 Sep;30(6):472-80. Review. German.

PMID:
16170677
10.

Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors.

Rudich A, Ben-Romano R, Etzion S, Bashan N.

Acta Physiol Scand. 2005 Jan;183(1):75-88. Review.

PMID:
15654921
11.

Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.

Guaraldi G, Zona S, Orlando G, Carli F, Stentarelli C, Luzi K, Garlassi E, Menozzi M, Bagni P, Adorni F.

Clin Drug Investig. 2011 Nov 1;31(11):759-67. doi: 10.2165/11593920-000000000-00000.

PMID:
21919542
12.

The mechanism of insulin resistance caused by HIV protease inhibitor therapy.

Murata H, Hruz PW, Mueckler M.

J Biol Chem. 2000 Jul 7;275(27):20251-4.

13.

Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy.

Chantry CJ, Hughes MD, Alvero C, Cervia JS, Meyer WA 3rd, Hodge J, Borum P, Moye J Jr; PACTG 1010 Team.

Pediatrics. 2008 Jul;122(1):e129-38. doi: 10.1542/peds.2007-2467. Epub 2008 Jun 2.

14.

Indinavir induces acute and reversible peripheral insulin resistance in rats.

Hruz PW, Murata H, Qiu H, Mueckler M.

Diabetes. 2002 Apr;51(4):937-42.

15.

Intracellular organization of insulin signaling and GLUT4 translocation.

Watson RT, Pessin JE.

Recent Prog Horm Res. 2001;56:175-93. Review.

PMID:
11237212
16.
17.
18.

[Metabolic syndrome and hyperlipidemia in HIV-positive patients].

Behrens GM.

Herz. 2005 Sep;30(6):458-66. German.

PMID:
16170675
19.

HIV-therapy associated lipodystrophy: experimental and clinical evidence for the pathogenesis and treatment.

Stankov MV, Behrens GM.

Endocr Metab Immune Disord Drug Targets. 2007 Dec;7(4):237-49. Review.

PMID:
18220944
20.

Effects of HIV protease inhibitor therapy on lipid metabolism.

Hui DY.

Prog Lipid Res. 2003 Mar;42(2):81-92. Review.

PMID:
12547652
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk